Next Article in Journal
Evolving Resection Strategies for Non-Small Cell Lung Cancers: Translating Trial Evidence to Real-World Practice
Previous Article in Journal
The Role of WWOX in Cancer Progression: Mechanisms and Therapeutic Potential
Previous Article in Special Issue
Inhibitor of DNA-Binding Protein 4 Suppresses Cancer Metastasis through the Regulation of Epithelial Mesenchymal Transition in Lung Adenocarcinoma
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Cancers
Volume 17
Issue 21
10.3390/cancers17213436
cancers-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite
Correction to Cancers 2019, 11(10), 1490.
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Correction

Correction: Simbulan-Rosenthal et al. CRISPR-Cas9 Knockdown and Induced Expression of CD133 Reveal Essential Roles in Melanoma Invasion and Metastasis. Cancers 2019, 11, 1490

by
Cynthia M. Simbulan-Rosenthal
1,
Ryan Dougherty
1,
Sahar Vakili
1,
Alexandra M. Ferraro
1,
Li-Wei Kuo
1,
Ryyan Alobaidi
1,
Leala Aljehane
1,
Anirudh Gaur
1,
Peter Sykora
2,
Eric Glasgow
3,
Seema Agarwal
4 and
Dean S. Rosenthal
1,*
1
Department of Biochemistry and Molecular & Cellular Biology, Georgetown University School of Medicine, Washington, DC 20007, USA
2
Amelia Technologies, Rockville, MD 20850, USA
3
Department of Oncology, Georgetown University School of Medicine, Washington, DC 20007, USA
4
Department of Pathology, Georgetown University School of Medicine, Washington, DC 20007, USA
*
Author to whom correspondence should be addressed.
Cancers 2025, 17(21), 3436; https://doi.org/10.3390/cancers17213436 (registering DOI)
Submission received: 11 October 2025 / Accepted: 13 October 2025 / Published: 27 October 2025
(This article belongs to the Special Issue Cancer Invasion and Metastasis)
Browse Figures
Versions Notes

Error in Figures

In the original publication [1], there were mistakes in Figures 1b and 4b as published. In Figure 1b (top panel), the mouse tumor images for Day 11 were inadvertently used for the Day 25 time point. In Figure 4b, which is a composite of three gels, lanes 9 and 10 are alternating GAPDH and T3 primers that should have been taken from Gel 3, but were mistakenly taken from Gel 1. The corrected Figure 1b and Figure 4b appear below. The three original gels for Figure 4b are now included in Supplementary Figure S5.

Error in Supplementary Materials

With this correction, the Supplementary Materials Part has been adjusted accordingly.
  • Supplementary Materials: The following are available online at https://www.mdpi.com/2072-6694/11/10/1490/s1, Figure S1: (a) CRISPR Cas9 pLenti plasmid from ABM and Gene Targets, (b) Frameshift mutation analysis; Figure S2: (a) Frameshift mutation analysis from Next Generation Sequencing and (b) visualization of allelic mutations at CRISPR target sites; Figure S3: Scans of whole gel western blots showing molecular weight sizes of relevant proteins (indicated in arrows) for Figures 1f, 2a, 3a, 4c, 5a, 6b, 6d, 6f, and 6g; Figure S4: Densitometry analysis of western blots; Figure S5: RT-PCR gel images for Figure 4b.
The authors state that the scientific conclusions are unaffected. This correction was approved by the Academic Editor. The original publication has also been updated.

Reference

  1. Simbulan-Rosenthal, C.M.; Dougherty, R.; Vakili, S.; Ferraro, A.M.; Kuo, L.-W.; Alobaidi, R.; Aljehane, L.; Gaur, A.; Sykora, P.; Glasgow, E.; et al. CRISPR-Cas9 Knockdown and Induced Expression of CD133 Reveal Essential Roles in Melanoma Invasion and Metastasis. Cancers 2019, 11, 1490. [Google Scholar] [CrossRef] [PubMed]
Cancers 17 03436 g001
Figure 1. Preferential survival and growth of MACS-sorted CD133(+) cells in mixed population xenografts, and sustained CD133 expression after reprogramming. GFP-CD133(+) and DsRed-CD133(−) cells were isolated by MACS (a), injected into the flanks of nude mice, and tumors were visualized and measured by Maestro in vivo imaging after indicated periods of time. p-values of <0.05 were considered statistically significant and represented with a single asterisk, while p < 0.01 are labeled with two asterisks (b). (c) CD133 expression of reprogrammed BAK-R MIC and BAK-P populations assessed by immunofluorescent staining with anti-CD133-PE for 3 weeks show that BAK-R, but not BAK-P melanoma cells, exhibit sustained CD133 expression. Representative images after immunofluorescent staining of BAK-P and BAK-R cells with anti-CD133-PE ((d), right panels) as well as qRT-PCR (e) and immunoblot (f) analyses showing elevated CD133 expression in BAK-R compared to BAK-P cells. CD133(+) Caco-2 colon cancer cells and CD133(−) 1205Lu melanoma cells served as positive and negative controls, respectively ((d); left panels).
Figure 1. Preferential survival and growth of MACS-sorted CD133(+) cells in mixed population xenografts, and sustained CD133 expression after reprogramming. GFP-CD133(+) and DsRed-CD133(−) cells were isolated by MACS (a), injected into the flanks of nude mice, and tumors were visualized and measured by Maestro in vivo imaging after indicated periods of time. p-values of <0.05 were considered statistically significant and represented with a single asterisk, while p < 0.01 are labeled with two asterisks (b). (c) CD133 expression of reprogrammed BAK-R MIC and BAK-P populations assessed by immunofluorescent staining with anti-CD133-PE for 3 weeks show that BAK-R, but not BAK-P melanoma cells, exhibit sustained CD133 expression. Representative images after immunofluorescent staining of BAK-P and BAK-R cells with anti-CD133-PE ((d), right panels) as well as qRT-PCR (e) and immunoblot (f) analyses showing elevated CD133 expression in BAK-R compared to BAK-P cells. CD133(+) Caco-2 colon cancer cells and CD133(−) 1205Lu melanoma cells served as positive and negative controls, respectively ((d); left panels).
Cancers 17 03436 g001
Cancers 17 03436 g004
Figure 4. (a) CD133-depleted partial CRISPR-Cas9 BAK-R T3 cells show decreased CD133 expression and are less invasive and metastatic than BAK-R-SC controls. CD133 positivity was determined by immunofluorescence staining in BAK-P, BAK-R, partial CRISPR-Cas9 knockdowns using three target sgRNAs and a scrambled sgRNA control. CD133+ Caco-2 colon cancer cells and 1205Lu cells served as positive and negative controls, respectively. Images were taken at 10× magnification. RT-PCR (b) and immunoblot analysis (c) show depletion of CD133 RNA and protein in BAK-R T3 compared to BAK-R SC or BAK-R cells. (d) Transwell cell invasion assays showed decreased cell invasion in CD133-depleted BAK-R T3 cells, compared to BAK-R, control SC sgRNA, or T1 and T2 cells. (e) Injection of zebrafish with a 1:1 mixture of BAK-R SC (red) and BAK-R CD133 knockdown T3 cells (green) and representative images after 5 days; (f) quantification of % metastasis to the zebrafish tail. *, **, *** represent p < 0.05 and p < 0.01, and p < 0.001, respectively.
Figure 4. (a) CD133-depleted partial CRISPR-Cas9 BAK-R T3 cells show decreased CD133 expression and are less invasive and metastatic than BAK-R-SC controls. CD133 positivity was determined by immunofluorescence staining in BAK-P, BAK-R, partial CRISPR-Cas9 knockdowns using three target sgRNAs and a scrambled sgRNA control. CD133+ Caco-2 colon cancer cells and 1205Lu cells served as positive and negative controls, respectively. Images were taken at 10× magnification. RT-PCR (b) and immunoblot analysis (c) show depletion of CD133 RNA and protein in BAK-R T3 compared to BAK-R SC or BAK-R cells. (d) Transwell cell invasion assays showed decreased cell invasion in CD133-depleted BAK-R T3 cells, compared to BAK-R, control SC sgRNA, or T1 and T2 cells. (e) Injection of zebrafish with a 1:1 mixture of BAK-R SC (red) and BAK-R CD133 knockdown T3 cells (green) and representative images after 5 days; (f) quantification of % metastasis to the zebrafish tail. *, **, *** represent p < 0.05 and p < 0.01, and p < 0.001, respectively.
Cancers 17 03436 g004
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Simbulan-Rosenthal, C.M.; Dougherty, R.; Vakili, S.; Ferraro, A.M.; Kuo, L.-W.; Alobaidi, R.; Aljehane, L.; Gaur, A.; Sykora, P.; Glasgow, E.; et al. Correction: Simbulan-Rosenthal et al. CRISPR-Cas9 Knockdown and Induced Expression of CD133 Reveal Essential Roles in Melanoma Invasion and Metastasis. Cancers 2019, 11, 1490. Cancers 2025, 17, 3436. https://doi.org/10.3390/cancers17213436

AMA Style

Simbulan-Rosenthal CM, Dougherty R, Vakili S, Ferraro AM, Kuo L-W, Alobaidi R, Aljehane L, Gaur A, Sykora P, Glasgow E, et al. Correction: Simbulan-Rosenthal et al. CRISPR-Cas9 Knockdown and Induced Expression of CD133 Reveal Essential Roles in Melanoma Invasion and Metastasis. Cancers 2019, 11, 1490. Cancers. 2025; 17(21):3436. https://doi.org/10.3390/cancers17213436

Chicago/Turabian Style

Simbulan-Rosenthal, Cynthia M., Ryan Dougherty, Sahar Vakili, Alexandra M. Ferraro, Li-Wei Kuo, Ryyan Alobaidi, Leala Aljehane, Anirudh Gaur, Peter Sykora, Eric Glasgow, and et al. 2025. "Correction: Simbulan-Rosenthal et al. CRISPR-Cas9 Knockdown and Induced Expression of CD133 Reveal Essential Roles in Melanoma Invasion and Metastasis. Cancers 2019, 11, 1490" Cancers 17, no. 21: 3436. https://doi.org/10.3390/cancers17213436

APA Style

Simbulan-Rosenthal, C. M., Dougherty, R., Vakili, S., Ferraro, A. M., Kuo, L.-W., Alobaidi, R., Aljehane, L., Gaur, A., Sykora, P., Glasgow, E., Agarwal, S., & Rosenthal, D. S. (2025). Correction: Simbulan-Rosenthal et al. CRISPR-Cas9 Knockdown and Induced Expression of CD133 Reveal Essential Roles in Melanoma Invasion and Metastasis. Cancers 2019, 11, 1490. Cancers, 17(21), 3436. https://doi.org/10.3390/cancers17213436

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Article metric data becomes available approximately 24 hours after publication online.
Back to TopTop